ANEMIC PATIENT AT GP’S OFFICE
https://doi.org/10.15829/1728-8800-2014-3-67-77
Abstract
In contemporary medicine anemia is not just a decrease of hemoglobin level, but risk factor for worse outcome in vascular patients. At the same time anemia usually is not stated in the diagnosis and is not registered in statistic reports. Anemia – is always a complication that is why it always requires diagnostic algorithm to explore the underlying reason. Low hemoglobin level must be always marked by general physician. However in practice this happens just in 25% cases. Due to time deficiency at outpatient visits there is a demand for algorithm to provide GP with. This article concerns such algorithms to investigate the patients with found low hemoglobin level.
About the Authors
A. L. Vertkin
Moscow State Medico-Stomatological University n.a. Evdokimov A.I. Moscow, Russia
Russian Federation
Russian Federation
N. O. Khovasova
Moscow State Medico-Stomatological University n.a. Evdokimov A.I. Moscow, Russia
Russian Federation
Russian Federation
E. D. Laryushkina
Moscow State Medico-Stomatological University n.a. Evdokimov A.I. Moscow, Russia
Russian Federation
Russian Federation
K. I. Shamaeva
Moscow State Medico-Stomatological University n.a. Evdokimov A.I. Moscow, Russia
Russian Federation
Russian Federation
References
1. Felker GM, Shaw LK, Stough WG, O’Connor CM. Am Heart J. 2006 Feb;151 (2):457–62.
2. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31 (15):1872–80.
3. Feinstein A. R. Pre-therapeutic classification of co-morbidity in chronic disease. Journal Chronic Disease 1970; 23 (7): 455–68.
4. Britt HC, Harrison CM, Miller GC, Knox SA. Prevalence and patterns of multimorbidity in Australia. MJA of Australia 2008; 189 (2): 72–7.
5. Schoenberg NE, Kim H, Edwards W, Fleming ST. Burden of Common Multiple-Morbidity Constellations on Out-of-Pocket Medical Expenditures among Older Adults. Gerontologist 2007; 47, 4: 423–37.
6. Seeman TE, Guralnik JM, Kaplan GA, et al. The health consequences of multiple morbidity in the elderly: the Alameda County Study. J Aging Health 1989; 1: 50–66.
7. Hematology: the Latest directory. Under the General Ed. K. M. Abdulkadyrova. Of Eksmo; SPb.: Publishing house Owl, 2004. S. Russian (Гематология: Новейший справочник. Под общ. ред. К. М. Абдулкадырова. Из-во Эксмо; СПб.: Изд-во Сова, 2004. 928с).
8. Melnikova I. Anaemia therapies. Nat Rev Drug Discov 2006; 5: 627–8.
9. Melis M, McLoughlin JM, Dean ЕМ. Correlations between neoadjuvant treatment, anemia, and perioperative complications in patients undergoing esophagectomy for cancer. J Surg Res 2009; 153: 114–20.
10. Saravana S, Rai А. Anemia of chronic disease in patients with rheumatoid arthritisuse of zinc protoporphyrin (ZPP) levels. J Rheumatol 2007; 34: 446.
11. Ruiz-Argьelles GJ, Dнaz-Hernбndez А, Manzano С. Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia. Hematology 2007; 12: 255–6.
12. Gouva С, Nikolopoulos Р, Ionnidis J, Siamopoulos К. Treating anemia early in renal failure patients slows the decline of renal funtion: a randomized controlled trial. Kidney Int 2004; 66: 753–60.
13. Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart 2008; 13: 379–86.
14. Geisser P, Muller A. Iron pharmacokinitics of iron salts and ferric hydroxidecarbohydrate complexes. Drug Research 1987;37:100-4.
15. Geisser P. Safety and Efficacy of Iron (III)-hydroxide Polymaltose Complex. A review of over 25 years of experience. Arzneimittel-Forschung (Drug Research) 2007; 57(6a):39–452.
16. Tobili JE, Brignoli R. Iron(III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia. Arzneimittel-Forschung (Drug Research) 2007; 57(6a):431–8.
17. Jacobs P, Fransman D, Coghlan P. Comparative bioavability of ferric carboxymaltose and ferrous sulphate in iron-deficient blood donors. J Clin Apher 1993: 8:89-95.
18. Jaber L, Rigler S, Taya A, et al. Iron polymaltose versus ferrous gluconate in the prevention of iron deficiency anemia of infancy. J Pediatr Hematol Oncol. 2010 Nov; 32(8):585-8.
19. Yasa B, Agaoglu L, Unuvar E. Efficacy, tolerability and acceptability of iron hydroxide polymaltose complex versus ferrous sulfate: a randomized trial in pediatric patients with iron deficiency anemia. Int. J. Pediatr. 2011: 524520. Epub 2011 Oct 31.
20. Walter T, Zacarias I, Yanez CG. Tolerance and acceptability in infants of iron polymaltose complex. Ars Medici 2005; 9:428-31.
21. Инструкция по медицинскому применению препарата “Феррум Лек”. http://www.vidal.ru/drugs/ferrum_lek~23506.
22. Ylmaz S, Uсar A. A review of the genotoxic and carcinogenic effects of aspartame: does it safe or not? Cytotechnology 2014. DOI 10.1007/s10616-013-9681-0.
23. Anker S.D, Comin-Colet J, Filippatos G. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009; 361:2436-48.
Review
For citations:
Vertkin A.L., Khovasova N.O., Laryushkina E.D., Shamaeva K.I. ANEMIC PATIENT AT GP’S OFFICE. Cardiovascular Therapy and Prevention. 2014;13(3):67-77. (In Russ.) https://doi.org/10.15829/1728-8800-2014-3-67-77
Views:
985
Email this article 
